October 25, 2023Open Access

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Key Points

Key points are not available for this paper at this time.

Abstract

Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT04501679; EudraCT number, 2019-004789-17.).

Perguntar à IA

Bookmark

View Full Paper

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Kwatra et al. (Wed,) studied this question.

synapsesocial.com/papers/69da7db10f32475823a3d5a7 https://doi.org/https://doi.org/10.1056/nejmoa2301333

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances2022 · 48 citations
2Lung volumes and forced ventilatory flows1993 · 5,306 citations
3Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study2018 · 244 citations
4European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo2017 · 267 citations
5Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus2020 · 122 citations